PMC:7228307 / 52503-53104
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id | tao:has_standard_notation |
---|---|---|---|---|---|---|
1063 | 267-272 | Gene | denotes | PD‐L1 | Gene:29126 | |
1064 | 584-587 | Gene | denotes | C1q | Gene:712 | |
1065 | 531-535 | Gene | denotes | FcγR | Gene:2213 | |
1066 | 135-139 | Gene | denotes | FcγR | Gene:2213 | |
1067 | 494-498 | Gene | denotes | FcγR | Gene:2213 | |
1068 | 74-78 | Gene | denotes | FcγR | Gene:2213 | |
1069 | 250-260 | Chemical | denotes | durvalumab | MESH:C000613593 | |
1070 | 278-289 | Chemical | denotes | anifrolumab | MESH:C582345 | |
1071 | 376-381 | Mutation | denotes | L234F | p.L234F | |
1072 | 415-420 | Mutation | denotes | L235E | p.L235E | |
1073 | 444-449 | Mutation | denotes | P331S | p.P331S |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T407 | 45-55 | Body_part | denotes | amino acid | http://purl.org/sig/ont/fma/fma82739 |
T408 | 221-232 | Body_part | denotes | amino acids | http://purl.org/sig/ont/fma/fma82739 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T886 | 0-1 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T887 | 20-23 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T888 | 45-64 | http://purl.obolibrary.org/obo/CHEBI_33708 | denotes | amino acid residues |
T889 | 45-64 | http://purl.obolibrary.org/obo/PR_000036907 | denotes | amino acid residues |
T890 | 74-76 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T891 | 135-137 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T892 | 267-272 | http://purl.obolibrary.org/obo/CLO_0008407 | denotes | PD‐L1 |
T893 | 494-496 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T894 | 531-533 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T895 | 588-598 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activation |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T5000 | 45-55 | Chemical | denotes | amino acid | http://purl.obolibrary.org/obo/CHEBI_33709 |
T20266 | 45-50 | Chemical | denotes | amino | http://purl.obolibrary.org/obo/CHEBI_46882 |
T44260 | 51-55 | Chemical | denotes | acid | http://purl.obolibrary.org/obo/CHEBI_37527 |
T10443 | 221-232 | Chemical | denotes | amino acids | http://purl.obolibrary.org/obo/CHEBI_33709 |
T57589 | 221-226 | Chemical | denotes | amino | http://purl.obolibrary.org/obo/CHEBI_46882 |
T8912 | 227-232 | Chemical | denotes | acids | http://purl.obolibrary.org/obo/CHEBI_37527 |
T75315 | 267-269 | Chemical | denotes | PD | http://purl.obolibrary.org/obo/CHEBI_74756 |
T36188 | 296-306 | Chemical | denotes | interferon | http://purl.obolibrary.org/obo/CHEBI_52999 |
LitCovid-sample-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T57 | 45-55 | Chemical | denotes | amino acid | http://purl.obolibrary.org/obo/CHEBI_33709 |
T58 | 221-232 | Chemical | denotes | amino acids | http://purl.obolibrary.org/obo/CHEBI_33709 |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes | pubann:has_HGVS_notation |
---|---|---|---|---|---|---|
1063 | 267-272 | Gene | denotes | PD‐L1 | Gene:29126 | |
1064 | 584-587 | Gene | denotes | C1q | Gene:712 | |
1065 | 531-535 | Gene | denotes | FcγR | Gene:2213 | |
1066 | 135-139 | Gene | denotes | FcγR | Gene:2213 | |
1067 | 494-498 | Gene | denotes | FcγR | Gene:2213 | |
1068 | 74-78 | Gene | denotes | FcγR | Gene:2213 | |
1069 | 250-260 | Chemical | denotes | durvalumab | MESH:C000613593 | |
1070 | 278-289 | Chemical | denotes | anifrolumab | MESH:C582345 | |
1071 | 376-381 | Mutation | denotes | L234F | p.L234F | |
1072 | 415-420 | Mutation | denotes | L235E | p.L235E | |
1073 | 444-449 | Mutation | denotes | P331S | p.P331S |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T299 | 0-204 | Sentence | denotes | A separate strategy has used combinations of amino acid residues from the FcγR‐binding regions of IgG2 and IgG4, which have restricted FcγR specificity, together with other binding‐inactivating mutations. |
T300 | 205-383 | Sentence | denotes | The lower hinge amino acids of the IgG1 mAbs durvalumab (anti‐PD‐L1) and anifrolumab (anti‐interferon‐α receptor; Table 4) were modified to mimic the lower hinge of IgG4 (L234F). |
T301 | 384-601 | Sentence | denotes | They additionally incorporated L235E in the lower hinge and P331S in the F/G loop of the CH2 domain to ablate FcγR binding by disrupting two major FcγR contact sites7 and also coincidently decreasing C1q activation.16 |
LitCovid-sample-UniProt
Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
---|---|---|---|---|---|
T704 | 267-272 | Protein | denotes | PD‐L1 | https://www.uniprot.org/uniprot/Q9NZQ7|https://www.uniprot.org/uniprot/Q9NUZ5|https://www.uniprot.org/uniprot/Q9EP73|https://www.uniprot.org/uniprot/Q6WEX4|https://www.uniprot.org/uniprot/Q66RK1|https://www.uniprot.org/uniprot/Q2V8D5|https://www.uniprot.org/uniprot/Q14CJ2|https://www.uniprot.org/uniprot/B4DU27|https://www.uniprot.org/uniprot/B2RBA2 |
T713 | 296-306 | Protein | denotes | interferon | https://www.uniprot.org/uniprot/P51527|https://www.uniprot.org/uniprot/P51526 |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T406 | 45-55 | Body_part | denotes | amino acid | http://purl.org/sig/ont/fma/fma82739 |
T407 | 221-232 | Body_part | denotes | amino acids | http://purl.org/sig/ont/fma/fma82739 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T299 | 0-204 | Sentence | denotes | A separate strategy has used combinations of amino acid residues from the FcγR‐binding regions of IgG2 and IgG4, which have restricted FcγR specificity, together with other binding‐inactivating mutations. |
T300 | 205-383 | Sentence | denotes | The lower hinge amino acids of the IgG1 mAbs durvalumab (anti‐PD‐L1) and anifrolumab (anti‐interferon‐α receptor; Table 4) were modified to mimic the lower hinge of IgG4 (L234F). |
T301 | 384-601 | Sentence | denotes | They additionally incorporated L235E in the lower hinge and P331S in the F/G loop of the CH2 domain to ablate FcγR binding by disrupting two major FcγR contact sites7 and also coincidently decreasing C1q activation.16 |